Day One Biopharmaceuticals’ Revenue at Risk: Heavy Dependence on Few Key Customers

Day One Biopharmaceuticals, Inc. (DAWN) has disclosed a new risk, in the Demand category.

Day One Biopharmaceuticals, Inc. faces a significant business risk due to its heavy reliance on a small number of large customers for revenue. During the nine months ending September 30, 2024, just three customers accounted for all of their net product revenue, with one customer alone representing 66.6%. This concentration risk means that the loss or reduction in demand from any of these customers could severely diminish net sales and negatively affect the company’s operating results. Furthermore, the entire accounts receivable balance is tied to these three customers, emphasizing the potential financial impact should any of them delay payments or cancel orders.

The average DAWN stock price target is $36.88, implying 150.54% upside potential.

To learn more about Day One Biopharmaceuticals, Inc.’s risk factors, click here.